High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis

Summary

Percutaneous coronary intervention (PCI) represents the most important treatment of coronary artery stenosis today. But instent restenosis (ISR) is a limitation for the outcome. Fas and Fas Ligand have been implicated in apoptosis and vessel wall inflammation. Their role in ISR is not known so far. In this prospective study we studied 137 patients with stable coronary artery disease who underwent elective PCI. Blood samples were taken directly before and 24 hours after PCI. Soluble (s)Fas and sFas Ligand serum levels were measured by ELISA. Restenosis was evaluated six to eight months later either by coronary angiography or by exercise testing. During the follow-up period, 18 patients (13%) developed ISR. At baseline, patients with ISR had significantly lower median sFas, as well as sFas Ligand levels compared to patients without ISR (sFAS: ISR 492 pg/ml, no ISR 967 pg/ml, p=0.014; sFAS Ligand: ISR: 26 pg/ml, no ISR: 42 pg/ml, p=0.001). After PCI median sFas levels significantly decreased in patients with ISR compared to patients without ISR [ISR: –152 pg/ml (IQR –36 to –227), no ISR: –38 pg/ml (IQR –173 to +150 pg/ml), p=0.03]. sFas Ligand levels after PCI significantly increased in ISR patients compared to patients without ISR [ISR: 14 pg/ ml (IQR –3 to +26 pg/ml), no ISR –6 pg/ml (IQR –22 to +21 pg/ml), p=0.014]. In conclusion, sFas and sFas Ligand seem to be associated with the development of ISR. Determination of serum levels before and after PCI might help identifying patients at higher risk of ISR.

Keywords

Inflammation - restenosis - stent

^* K.K. and F.W. contributed equally to the study.

• References

• 1 Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-224.
• 2 Abbott JD, Voss MR, Nakamura M. et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50: 2029-2036.
• 3 Goy JJ, Stauffer JC, Siegenthaler M. et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.
• 4 Simonton CA, Brodie B, Cheek B. et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group. J Am Coll Cardiol 2007; 50: 1214-1222.
• 5 Cosgrave J, Melzi G, Corbett S. et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007; 49: 2320-2328.
• 6 Li JJ, Nie SP, Zhang CY. et al. Is inflammation a contributor for coronary stent restenosis?. Med Hypotheses 2007; 68: 945-951.
• 7 Katsaros KM, Speidl WS, Kastl SP. et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008; 6: 508-513.
• 8 Katsaros KM, Kastl SP, Zorn G. et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and –9. JACC Cardiovasc Interv 2010; 3: 90-97.
• 9 Vivanco F, Martin-Ventura JL, Duran MC. et al. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res 2005; 4: 1181-1191.
• 10 Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47 (Suppl. 08) C19-31.
• 11 Danesh J, Wheeler JG, Hirschfield GM. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
• 12 Blanco-Colio LM, Martin-Ventura JL, Vivanco F. et al. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res 2006; 72: 18-29.
• 13 Mano T, Luo Z, Suhara T. et al. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions. Hum Gene Ther 2000; 11: 1625-1635.
• 14 Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther 2004; 4: 33-39.
• 15 Luo Z, Garron T, Palasis M. et al. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther 2001; 12: 2191-2202.
• 16 Luo Z, Sata M, Nguyen T. et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999; 99: 1776-1779.
• 17 Sata M, Perlman H, Muruve DA. et al. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA 1998; 95: 1213-1217.
• 18 Matter CM, Chadjichristos CE, Meier P. et al. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 2006; 113: 1879-1887.
• 19 Brunner T, Mogil RJ, LaFace D. et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444.
• 20 Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
• 21 Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4: 415-420.
• 22 Chan SW, Hegyi L, Scott S. et al. Sensitivity to Fas-mediated apoptosis is determined below receptor level in human vascular smooth muscle cells. Circ Res 2000; 86: 1038-1046.
• 23 Niessner A, Hohensinner PJ, Rychli K. et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-796.
• 24 Boos CJ, Balakrishnan B, Blann AD. et al. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008; 6: 1841-1850.
• 25 Isner JM, Kearney M, Bortman S. et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711.
• 26 Kastrati A, Schomig A, Elezi S. et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999; 100: 1285-1290.
• 27 Dupont WD, Plummer Jr. WD. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-128.
• 28 Rothman K, Greenland S. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998
• 29 Xu YG, Zhou SH, Li YG. et al. The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression. Cardiovasc Drugs Ther 2007; 21: 145-153.
• 30 Blanco-Colio LM, Martin-Ventura JL, Sol JM. et al. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004; 43: 1188-1194.
• 31 Perlman H, Maillard L, Krasinski K. et al. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997; 95: 981-987.
• 32 Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res 2000; 87: 184-188.
• 33 Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
• 34 Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 2000; 20: 309-316.
• 35 Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology 2007; 120: 133-139.
• 36 Suda T, Hashimoto H, Tanaka M. et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
• 37 Tanaka M, Itai T, Adachi M. et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
• 38 Schneider P, Holler N, Bodmer JL. et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
• 39 Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 1999; 162: 480-485.
• 40 Kiener PA, Davis PM, Rankin BM. et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997; 159: 1594-1598.
• 41 Liles WC, Kiener PA, Ledbetter JA. et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-440.
• 42 Imanishi T, Han DK, Hofstra L. et al. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/macrophage. Atherosclerosis 2002; 161: 143-151.
• 43 Papoff G, Cascino I, Eramo A. et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-4630.
• 44 Proussakova OV, Rabaya NA, Moshnikova AB. et al. Oligomerization of soluble Fas antigen induces its cytotoxicity. J Biol Chem 2003; 278: 36236-36241.